Library

Low-dose cannabidiol increases plasma concentrations of amitriptyline: A clinical drug-drug interaction study.

15 December 2025. doid: 10.1002/bcp.70415

Gorbenko AA, Post TE, Strugala PK, Klaassen ES, Klumpers LE, de Visser SJ, Sempio C, Klawitter J, Heuberger JAAC, Groeneveld GJ

View publication

Cannabidiol (CBD), the main non-intoxicating compound from the cannabis plant, is regularly used by patients with chronic pain who also take analgesics. CBD has previously been shown to inhibit CYP-mediated drug metabolism. This study aimed to characterize the potential pharmacokinetic interaction of CBD with amitriptyline and tramadol, two commonly used analgesics.

Advancing the boundaries of clinical drug development

Wondering how we can help you? Reach out to us.

Get in contact
contact